News
A panelist discusses how axatilimab, a humanized IgG4 monoclonal antibody targeting CSF-1 receptors on monocytes and macrophages, showed promising results in the AGAVE-201 trial for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback